TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cronos Australia Ltd. ( (AU:VIT) ) has provided an update.
Cronos Australia Ltd. reported a slight increase in total revenues to $124 million for the year ended 30 June 2025, despite a decrease in net profit due to industry-wide gross margin pressures and increased expenses. The company experienced a notable rise in medical consultation and service fees, largely attributed to the acquisition of Candor Medical and the continued growth of Doctors on Demand. While the medicinal cannabis industry faced challenges such as price compression, Cronos Australia’s strategic investments in platforms like Canview and Doctors on Demand are expected to drive future growth. The company also announced a dividend payment and highlighted a decrease in total liabilities and expenses, reflecting improved financial management.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
More about Cronos Australia Ltd.
Average Trading Volume: 243,037
Technical Sentiment Signal: Sell
Current Market Cap: A$45.03M
Learn more about VIT stock on TipRanks’ Stock Analysis page.